Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multivalent pneumococcal conjugate formulation 1
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Multivalent pneumococcal conjugate formulation 1 is a vaccine developed by Pfizer. It is designed to induce an immune response against various serotypes of *Streptococcus pneumoniae* to prevent pneumococcal disease. This formulation is currently undergoing evaluation in a Phase 1b clinical trial to assess its safety and immunogenicity in healthy Japanese adults.
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on multivalent pneumococcal conjugate formulation 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multivalent pneumococcal conjugate formulation 1.